# 2025-21187: Company Applies to Legally Mass-Produce Controlled Drugs

2025-21187, Bulk Manufacturer of Controlled Substances Application: Irvine Labs Inc., is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-11-26, effective Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before January 26, 2026. Such persons may also file a written request for a hearing on the application on or before January 26, 2026. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21187
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21187
- Title: Bulk Manufacturer of Controlled Substances Application: Irvine Labs Inc.
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 54385
- Published: 2025-11-26
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before January 26, 2026. Such persons may also file a written request for a hearing on the application on or before January 26, 2026.
- Comments close: 2026-01-26
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Company Applies to Legally Mass-Produce Controlled Drugs

## Summary

Irvine Labs Inc. wants to make large amounts of some powerful, tightly controlled drugs like psilocybin and LSD for research. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies but also means careful government oversight and no quick cash changes for now.

## Abstract

Irvine Labs Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

- Application to Manufacture Schedule I Drugs: mixed, low. On October 29, 2025, Irvine Labs Inc. applied to be registered as a bulk manufacturer for several Schedule I substances, including ibogaine, lysergic acid diethylamide (LSD), mescaline, peyote, diethyltryptamine (DET), dimethyltryptamine (DMT), psilocybin, and psilocyn. The company says it plans to…
- Comment and Hearing Deadline: benefit, low. Registered bulk manufacturers of the affected drug classes, and applicants, may submit electronic comments or objections and may file written requests for a hearing on this application on or before January 26, 2026. Comments must be submitted through https://www.regulations.gov.
- Registration Limited to Research Use: cost, low. The notice states that, if registered, Irvine Labs' authorization would be limited to bulk manufacture of the listed drug codes for research and development internally and for distribution to its research customers. The registration would not authorize any other activities for those drug codes.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-21187 on federalregister.gov](https://www.federalregister.gov/documents/2025/11/26/2025-21187/bulk-manufacturer-of-controlled-substances-application-irvine-labs-inc)
- [2025-21187 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-11-26/pdf/2025-21187.pdf)

## Related
- [Previous: 2025-21186, Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solut…](https://policyrisk.com/federal-register/2025-21186)
- [Next: 2025-21188, Proposal Review; Notice of Meetings](https://policyrisk.com/federal-register/2025-21188)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21187 (as of 2026-06-08).
